KOL Perspectives: Upadacitinib for Rheumatoid Arthritis by AbbVie, Pfizer, Lilly, Gilead, Galapagos
Orbisresearch.com published “Upadacitinib for Rheumatoid Arthritis Market” from its database. The report focuses on major leading industry players with information such as company profiles, product picture and specification.
(EMAILWIRE.COM, October 24, 2018 ) This KOL Insight briefing focuses on perceptions of novel upadacitinib data in RA.
The briefing includes analysis of KOL opinion on the following topic areas -
- Efficacy & safety of upadacitinib in the SELECT COMPARE trial (csDMARD-IR patients)
- Efficacy & safety of upadacitinib as a monotherapy in SELECT MONOTHERAPY trial (MTX-IR patients)
- Views on dose response for upadacitinib
Key Players:
• AbbVie
• Pfizer
• Lilly
• Gilead
• Galapagos
Get Sample Copy of this Report@ http://www.orbisresearch.com/contacts/request-sample/2350558
Key Highlights:
- Majority of KOLs had a positive opinion of upadacitinib’s efficacy, particularly vs. adalimumab, in the SELECT COMPARE trial
- Most KOLs had a favorable opinion of Week 12 upadacitinib data vs. adalimumab from the SELECT COMPARE trial
- KOLs appeared unsure of upadacitinib’s comparative efficacy vs. other JAK inhibitors, with many citing the need for head-to-head studies.
Scope:
- The insight briefing is based on Sociable Pharma’s analysis of primary research with our RA key opinion leaders (KOLs)
- In total, we conducted interviews with 10 KOLs: Five Europe-based & five US-based
- Interviews performed in Q2 2018
- KOL data is analyzed to produce: Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts.
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2350558
Reasons to buy:
- Combines Qualitative & semi-quantitative insight from key opinion leaders on "Upadacitinib for Rheumatoid Arthritis"
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of rheumatoid arthritis
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Key Points from TOC:
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
Get More Access with Full TOC@ http://www.orbisresearch.com/reports/index/kol-perspectives-upadacitinib-for-rheumatoid-arthritis
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
The briefing includes analysis of KOL opinion on the following topic areas -
- Efficacy & safety of upadacitinib in the SELECT COMPARE trial (csDMARD-IR patients)
- Efficacy & safety of upadacitinib as a monotherapy in SELECT MONOTHERAPY trial (MTX-IR patients)
- Views on dose response for upadacitinib
Key Players:
• AbbVie
• Pfizer
• Lilly
• Gilead
• Galapagos
Get Sample Copy of this Report@ http://www.orbisresearch.com/contacts/request-sample/2350558
Key Highlights:
- Majority of KOLs had a positive opinion of upadacitinib’s efficacy, particularly vs. adalimumab, in the SELECT COMPARE trial
- Most KOLs had a favorable opinion of Week 12 upadacitinib data vs. adalimumab from the SELECT COMPARE trial
- KOLs appeared unsure of upadacitinib’s comparative efficacy vs. other JAK inhibitors, with many citing the need for head-to-head studies.
Scope:
- The insight briefing is based on Sociable Pharma’s analysis of primary research with our RA key opinion leaders (KOLs)
- In total, we conducted interviews with 10 KOLs: Five Europe-based & five US-based
- Interviews performed in Q2 2018
- KOL data is analyzed to produce: Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts.
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2350558
Reasons to buy:
- Combines Qualitative & semi-quantitative insight from key opinion leaders on "Upadacitinib for Rheumatoid Arthritis"
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of rheumatoid arthritis
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Key Points from TOC:
Executive Summary
Background
Research Panel Composition
Results & Implications
Appendix
Get More Access with Full TOC@ http://www.orbisresearch.com/reports/index/kol-perspectives-upadacitinib-for-rheumatoid-arthritis
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results